A5046408306- Inflammatory Myopathies and Dermatomyositis
- Cancer Immunotherapy and Biomarkers
- Systemic Lupus Erythematosus Research
- Multiple Myeloma Research and Treatments
- Orthopedic Infections and Treatments
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Atherosclerosis and Cardiovascular Diseases
- Radiopharmaceutical Chemistry and Applications
- Hypertrophic osteoarthropathy and related conditions
- Hematological disorders and diagnostics
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cutaneous Melanoma Detection and Management
- Systemic Sclerosis and Related Diseases
- Brain Metastases and Treatment
- Infective Endocarditis Diagnosis and Management
- Melanoma and MAPK Pathways
- Agriculture and Farm Safety
- Literature, Culture, and Aesthetics
- Genomics and Rare Diseases
- Advanced Breast Cancer Therapies
- Salivary Gland Disorders and Functions
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
2016-2024
Hospital Universitario de Gran Canaria Doctor Negrín
2018-2019
University of Buenos Aires
2019
National University of the Arts
2019
Luigi Sacco Hospital
2015
Hospital Fernández
2006
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including
BRCA1/2 mutations in Latin America are scarcely documented and serious need of knowledge about the spectrum BRCA pathogenic variants, information which may alter clinical practice subsequently improve patient outcome. In addition, search for data on testing policies different regions constitutes a fundamental strength present study, analyzes gene sequences large rearrangements 940 probands with familial and/or personal history breast/ovary cancer (BOC). non-mutated DNA samples, Multiplex...
Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in management non-small cell carcinoma are focused on discovery targeted therapies and novel immunotherapy strategies for patients with advanced disease. Treatment anti PD-(L)1 immune checkpoint inhibitors requires development predictive biomarkers to select those that can most benefit from these therapies. Several immunohistochemical have been developed different technological platforms. However, useful...
Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with discovery targeted agents. However, only small proportion patients carry activating mutations; until recently conventional chemotherapy angiogenesis inhibitors were preferred treatment for vast majority patients. Now, successful experience anti-PD-1 agents may opened door to novel previously unexplored dimension...
<title>Abstract</title> Purpose Geriatric 8 (G8) is a screening tool to identify frail older patients with cancer. Functional decline (FD) determinant in quality of life and survival. We aim determine the predictive value G8 for FD cancer after new treatment, its prognostic 1-year mortality, severe adverse events, hospitalizations. Methods Prospective multicenter cohort study ≥ 65 years old receiving oncologic treatment two hospitals assessed baseline G8. Cut-off G8: ≤14. status was using...
En tiempos recientes, el desarrollo extraordinario de productos televisivos seriales, que han revolucionado los modos producción, difusión y consumo, suscita interés académico abre campos investigación hasta ahora poco explorados. Nuevas investigaciones señalan la inadecuación trasladar sin más las categorías analíticas del cine a televisión comienzan ocuparse aquellos recursos expresivos específicos ficción televisiva. El presente artículo se propone revisar esas lecturas, con fin realizar...
<h3>Background</h3> The presence of muscle weakness and anti-Jo1 anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies, are evaluated in the new EULAR/ACR proposed classification criteria for adult juvenile idiopathic inflammatory myopathies (IIM), as well Solomon antisynthetase syndrome (ASSD) diagnosis (1, 2). That favors an overlapping both fulfillment; however, ASSD not considered among IIM subgroups classification. Anti-Jo1 ARS positivity is highest weighted criterion criteria;...
Abstract Background: NIVO (anti-PD-1) was initially approved in the USA as a second-line treatment for MEL based on results of phase III CheckMate 037 trial, which enrolled patients (pts) who progressed after prior IPI (anti-CTLA-4) therapy. The this trial showed significantly improved tumor response with vs. chemotherapy; at minimum follow-up 2 years, grade 3/4 treatment-related adverse events (AEs) were reported 14% NIVO-treated pts. We report initial overall survival (OS) and safety data...
<h3>Background:</h3> The antisynthetase syndromes (ASSD) are characterized by the presence of anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies and clinical features including myositis, arthritis, interstitial lung disease (ILD), Raynaud's phenomenon (RP), mechanic hands (MH), fever. Two aSSD diagnosis criteria have been developed; those proposed Connors, stricter Solomon (1, 2). Additionally, other symptoms connective tissue diseases (CTD) can be present. <h3>Objectives:</h3> To...
<h3>Background:</h3> The antisynthetase syndromes (ASSD) are characterized by the presence of anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies; which difficult binding amino acids to during protein synthesis. ARS can be detected indirect immunofluorescence (IIF), and identified immunoblot assay ELISA (Enzyme-Linked ImmunoSorbent Assay) immunoblotting. main clinical features ASSD myositis, arthritis, interstitial lung disease, Raynaud's phenomenon, mechanic hands, fever. Two...
Metastatic melanoma represents an aggressive tumor with overall poor prognosis. Targeted agents and immunotherapy have become the standard of care. Approximately 50-60 % melanomas harbor BRAF mutations. Vemurafenib dabrafenib are inhibitors, a group drugs that will certainly expand, obtained FDA approval after showing increased response rate (ORR), progression free survival (PFS) (OS) when compared to chemotherapy. Trametinib was first MEK inhibitor approved as single agent in 2013, but...
Mucosal melanomas are rare and associated with poor prognosis. Importantly, primary mucosal melanoma is clinically biologically different from cutaneous melanoma. Complete surgical resection the standard of care treatment for localized However, given usual anatomic locations where arise, including head neck anorectal mucosa, optimal margins challenging post-surgical local recurrences not uncommon. Adjuvant radiation therapy diminishes recurrence rate but does seem to improve overall survival...